Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jerrelle Copeland

Internal Medicine Gold Canyon, AZ Medical Doctor

NPI 1790784643 CMS profile 36309

6788 S Kings Ranch Rd Ste 1, Gold Canyon, AZ 85118

Open in the dashboard

General payments

$4,384

219 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jerrelle Copeland of Gold Canyon, AZ is reported in the CMS Open Payments database as having received $4,384 across 219 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,152 43
2024 General $419 21
2023 General $654 33
2022 General $521 29
2021 General $559 34
2020 General $345 21
2019 General $734 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jerrelle Copeland
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jerrelle Copeland were reported at $1,152. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jerrelle Copeland Internal Medicine median Middle half National median
2019 $734 $159 $48–$570 $163
2020 $345 $119 $33–$402 $114
2021 $559 $135 $37–$521 $132
2022 $521 $141 $42–$496 $149
2023 $654 $149 $45–$519 $160
2024 $419 $154 $47–$537 $164
2025 $1,152 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $811 34 payments
  2. GlaxoSmithKline, LLC. $478 25 payments
  3. AbbVie, Inc. $420 21 payments
  4. Amgen Inc. $312 20 payments
  5. Intra-Sana Laboratories $231 7 payments
  6. AstraZeneca Pharmaceuticals LP $211 14 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $211 12 payments
  8. Abbott Laboratories $194 8 payments
  9. Inspire Medical Systems, Inc. $150 3 payments
  10. Lilly USA, LLC $140 9 payments
  11. Other $1,227 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,326 213 payments
  2. Education $41 5 payments
  3. Entertainment $17 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $454 22 payments
  2. TRELEGY ELLIPTA $385 20 payments
  3. Prolia $248 16 payments
  4. EVENITY $247 16 payments
  5. RYBELSUS $246 15 payments
  6. RELTONE 200 MG $231 7 payments
  7. GLYCATE $231 7 payments
  8. RELTONE 400 MG $231 7 payments
  9. UBRELVY $173 8 payments
  10. INSPIRE $150 3 payments
  11. Other $3,011 165 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 127 drugs

Part D claims

6,724

Median for Internal Medicine: 777

Drug cost

$492,321

Median for Internal Medicine: $73,373

Branded share of claims

19.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 82 $101,918
Ozempic Semaglutide Brand 71 $82,854
Eliquis Apixaban Brand 60 $59,141
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 40 $41,873
Wegovy Semaglutide Brand 19 $26,739
Gemtesa Vibegron Brand 32 $24,453
Xarelto Rivaroxaban Brand 22 $23,573
Trulicity Dulaglutide Brand 11 $11,708
Jardiance Empagliflozin Brand 12 $10,429
Levothyroxine Sodium Generic 448 $4,802

The 10 drugs with the highest cost, of 127 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$561,808

Of which drugs: $502

Medicare patients

827

Average age 76

Services billed

10,906

566 women, 261 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Ischemic heart disease 34%
Chronic kidney disease 27%
Diabetes 26%
Osteoporosis 24%
Atrial fibrillation 22%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 65 229 $220
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 80 318 $220
Injection, ketorolac tromethamine, per 15 mg J1885 Office 53 128 $61

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $71
$71 40 —
Veozah
  • Astellas Pharma US Inc $51
$51 — —
Crysvita
  • Kyowa Kirin, Inc. $29
$29 — —
SHINGRIX
  • GlaxoSmithKline, LLC. $19
$19 — —
UBRELVY
  • AbbVie, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

219 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record